azetidin-3-ylmethanol trifluoroacetic acid | 928038-37-3

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: azetidin-3-ylmethanol trifluoroacetic acid
• 英文别名: 3-(Hydroxymethyl)azetidine trifluoroacetate；azetidin-3-ylmethanol;2,2,2-trifluoroacetic acid
• CAS: 928038-37-3
• 化学式: C₂HF₃O₂*C₄H₉NO
• 分子量: 201.146
• InChiKey: FEPPMRMBJWMXBE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.17
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.83
• 拓扑面积：
  69.6
• 氢给体数：
  3
• 氢受体数：
  7

反应信息

• 作为反应物：
  描述：

  2-氰甲基苯甲酸甲酯 、 azetidin-3-ylmethanol trifluoroacetic acid 在 N,N-二异丙基乙胺 作用下， 以 二甲基亚砜 为溶剂， 以37 %的产率得到methyl 2-cyano-4-[3-(hydroxymethyl)azetidin-1-yl]benzoate
  参考文献：
  名称：

  WO2024054591A1

  摘要：

  公开号：
• 作为产物：
  描述：

  三氟乙酸 、 3-羟甲基氮杂环丁烷-1-羧酸叔丁酯 以 二氯甲烷 为溶剂， 反应 12.0h， 以10.1 g的产率得到azetidin-3-ylmethanol trifluoroacetic acid
  参考文献：
  名称：

  [EN] RAPIDLY ACCELERATING FIBROSARCOMA PROTEIN DEGRADING COMPOUNDS AND ASSOCIATED METHODS OF USE
  [FR] COMPOSÉS DE DÉGRADATION DE PROTÉINE DE FIBROSARCOME RAPIDEMENT ACCÉLÉRÉ ET LEURS PROCÉDÉS D'UTILISATION

  摘要：

  本文描述了作为快速加速纤维肉瘤（Raf，如c-Raf、A-Raf和/或B-Raf）调节剂的双功能化合物。具体来说，本公开的异双功能化合物在一端含有结合到cereblon E3泛素连接酶的部分，另一端含有结合Raf的部分，使目标蛋白质靠近泛素连接酶以实现目标蛋白质的降解（和抑制）。本公开的异双功能化合物表现出与目标蛋白质的降解/抑制相关的广泛的药理活性。由于目标蛋白质异常调节导致的疾病或疾病可以通过本公开的化合物和组合物进行治疗或预防。

  公开号：

  WO2022047145A1

文献信息

• [EN] POLYCYCLIC COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF RAPIDLY ACCELERATED FIBROSARCOMA POLYPEPTIDES<br/>[FR] COMPOSÉS POLYCYCLIQUES ET MÉTHODES POUR LA DÉGRADATION CIBLÉE DE POLYPEPTIDES DU FIBROSARCOME RAPIDEMENT ACCÉLÉRÉ
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2020051564A1

  公开（公告）日：2020-03-12

  The present disclosure relates to bifunctional compounds, ULM— L—PTM, which find utility as modulators of Rapidly Accelerated Fibrosarcoma (RAF, such as c-RAF, A- RAF and/or B-RAF; the target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a Von Hippel-Lindau, cereblon, Inhibitors of Apotosis Proteins or mouse double-minute homolog 2 ligand which binds to the respective E3 ubiquitin ligase and on the other end a moiety which binds the target protein RAF, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein, or the constitutive activation of the target protein, are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物ULM—L—PTM，其作为快速加速纤维肉瘤（RAF，如c-RAF、A-RAF和/或B-RAF；目标蛋白）的调节剂具有实用性。具体而言，本公开涉及含有一端结合到相应E3泛素连接酶的Von Hippel-Lindau、cereblon、凋亡抑制蛋白或鼠双分子同源物2配体的双功能化合物，另一端结合到目标蛋白RAF的部分，使得目标蛋白与泛素连接酶靠近，以实现目标蛋白的降解（和抑制）。本公开展示了与目标蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由目标蛋白的聚集或积累，或目标蛋白的构成性激活导致的疾病或紊乱。
• Process for preparing phenoxypyridine derivatives
  申请人：Nagai Mitsuo

  公开号：US20080214815A1

  公开（公告）日：2008-09-04

  A process for preparing a compound represented by the formula (I): comprising reacting a compound represented by the formula (II) or salt thereof: with a compound represented by the formula (III): in the presence of a condensation reagent, wherein R 1 represents 1) optionally substituted azetidin-1-yl, 2) optionally substituted pyrrolidin-1-yl, 3) optionally substituted piperidin-1-yl, etc.; R 2 , R 3 , R 4 and R 5 may be the same or different and each represents hydrogen or fluorine; and R 6 represents hydrogen or fluorine.

  制备一种由化学式(I)表示的化合物的方法： 包括将由化学式(II)表示的化合物或其盐： 与由化学式(III)表示的化合物： 在缩合试剂的存在下反应， 其中R 1 代表1）可选择地取代的氮杂环丙烷-1-基，2）可选择地取代的吡咯烷-1-基，3）可选择地取代的哌啶-1-基等；R 2 ，R 3 ，R 4 和R 5 可以相同也可以不同，每个代表氢或氟；而R 6 代表氢或氟。
• [EN] MACROMOLECULE-SUPPORTED AMINOBENZAZEPINE COMPOUNDS<br/>[FR] COMPOSÉS D'AMINOBENZAZÉPINE À SUPPORT MACROMOLÉCULAIRE
  申请人：BOLT BIOTHERAPEUTICS INC

  公开号：WO2020252254A1

  公开（公告）日：2020-12-17

  The application provides macromolecule-supported compounds of Formula I or III comprising a macromolecular support linked by conjugation to one or more aminobenzazepine derivatives. The application also provides aminobenzazepine derivative intermediate compositions of Formula II comprising a reactive functional group. Such intermediate compositions are suitable substrates for formation of the macromolecule-supported compounds through a linker or linking moiety. The application further provides compositions comprising the macromolecule-supported compounds, as well as methods of treating cancer with the macromolecule-supported compounds.

  该应用程序提供了由共轭连接到一种或多种氨基苯并二氮杂环衍生物的大分子支持的化合物，其化学式为I或III。该应用程序还提供了具有反应性功能基团的化学式II的氨基苯并二氮杂环衍生物中间体组合物。这种中间体组合物适合通过连接物或连接基团形成大分子支持的化合物。该应用程序还提供了包含大分子支持化合物的组合物，以及使用这些大分子支持化合物治疗癌症的方法。
• [EN] MODULATORS OF ESTROGEN RECEPTOR PROTEOLYSIS AND ASSOCIATED METHODS OF USE<br/>[FR] MODULATEURS DU RÉCEPTEUR DES ŒSTROGÈNES DE PROTÉOLYSE ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS INC

  公开号：WO2018140809A1

  公开（公告）日：2018-08-02

  The present disclosure relates to bifunctional compounds, which find utility as modulators of estrogen receptor (target protein). In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a cereblon, Von Hippel-Lindau ligase-binding moiety, Inhibitors of Apotosis Proteins, or mouse double-minute homolog 2 ligand, which binds to the respective E3 ubiquitin ligase, and on the other end a moiety which binds the target protein, such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of target protein. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of target protein. Diseases or disorders that result from aggregation or accumulation of the target protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为雌激素受体（靶蛋白）的调节剂具有实用性。具体而言，本公开涉及包含一端为 cereblon、Von Hippel-Lindau 配体结合基团、凋亡抑制蛋白或鼠双分子同源物 2 配体的双功能化合物，该化合物与相应的 E3 泛素连接酶结合，并且另一端含有结合靶蛋白的基团，使得靶蛋白与泛素连接酶靠近，以实现对靶蛋白的降解（和抑制）。本公开展示了与靶蛋白的降解/抑制相关的广泛药理活性范围。本公开的化合物和组合物用于治疗或预防由靶蛋白聚集或积累导致的疾病或紊乱。
• Novel pyridine derivatives and pyrimidine derivatives (3)
  申请人：Matsushima Tomohiro

  公开号：US20080319188A1

  公开（公告）日：2008-12-25

  A compound represented by the following formula, a salt thereof or a hydrate of the foregoing has an excellent hepatocyte growth factor receptor (HGFR) inhibitory activity, and exhibits anti-tumor activity, angiogenesis inhibitory activity and cancer metastasis inhibitory activity. [R 1 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; R 2 and R 3 represent hydrogen; R 4 , R 5 , R 6 , and R 7 may be the same or different and each represents hydrogen, halogen, C 1-6 alkyl or the like; R 8 represents hydrogen or the like; R 9 represents a 3- to 10-membered non-aromatic heterocyclic group or the like; n represents an integer of 1 or 2; X represents —CH═, nitrogen or the like.]

  以下化合物，其盐或水合物，具有优异的肝细胞生长因子受体（HGFR）抑制活性，表现出抗肿瘤活性、抑制血管生成活性和癌症转移抑制活性。[其中，R1代表3-至10-成员的非芳香族杂环基团等；R2和R3代表氢；R4、R5、R6和R7可以相同或不同，每个代表氢、卤素、C1-6烷基或类似物；R8代表氢或类似物；R9代表3-至10-成员的非芳香族杂环基团等；n代表1或2的整数；X代表-CH═，氮或类似物。]